NEUREN PHARMACEUTICALS LIMITED - News & Media

5.76%

$13.10

Market Cap $1.629B

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

MEMPHASYS LIMITED

Memphasys Ltd is a listed Australian MedTech company (ASX: MEM) focussed on reproductive biotechnology. Driven by market needs, Memphasys is developing a portfolio of device, diagnostic and media products that address human and animal reproduction issues.

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.10		Change -0.800(5.76%)		Mkt cap ! $1.629B

Open	High	Low	Value	Volume
$13.95	$13.96	$12.88	$9.534M	725.6K

Buyers (Bids)

No.	Vol.	Price($)
1	266	$13.10

Sellers (Offers)

Price($)	Vol.	No.
$13.15	1619	2

View Market Depth

No.	Vol.	Price($)
1	667	13.080
2	154	13.000
1	77	12.930
1	39	12.920
1	21	12.900

Price($)	Vol.	No.
13.190	1305	1
13.560	2250	1
13.880	748	1
14.000	60	1
14.020	10000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED - News & Media

Articles & Videos

FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome

Neuren set for FDA talks on trial to treat developmental genetic disorders

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Neuren flags Q4 DAYBUE sales of US$87m but shares take nosedive right out the gate

"Things are worse": Neuren Pharmaceuticals shares sink as wonder drug questioned

Neuren Pharmaceuticals completes enrolment in Angelman syndrome phase two trial

Neuren Pharma Reports positive results in phase 2 trial for NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) expands global partnership with Acadia

Neuren Pharamceuticals (ASX:NEU) opens first US site for Prader-Willi trial

Buyers (Bids)

Sellers (Offers)

Top Stories